Go to deals
Healthcare

CIT Safety & Health Research Lab has acquired the assets of LAB Research Inc.

CIT Safety & Health Research Laboratories (CIT) has acquired all the assets of LAB Research Inc.

CIT is part of the holding company Applied Biology Company (ABC). Through this acquisition, the newly created CIT-LAB group becomes one of the top five preclinical CROs. CIT is an established player in the field of preclinical contract research with more than forty years of experience.

LAB Research is a Canadian global non-clinical contract research organization that provides contract research services to the pharmaceutical, biotechnology, agro-chemical, petrochemical and industrial markets. LAB Research supports the development of its customers' products from three state-of-the-art facilities located in Canada, Denmark and Hungary.

Oaklins' team in Canada advised the buyer in this transaction.

Parties

Talk to the deal team

Sebastien Nadeau

Managing Partner
Montreal, Canada
Oaklins Canada

Related deals

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Healthcare

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.

Learn more
Afric Phar has been acquired by Pharma Capital
Healthcare

Afric Phar has been acquired by Pharma Capital

Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.

Learn more
Xiel Limited has been acquired by MIS Healthcare
Private Equity | Healthcare

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Learn more